Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2011 Mar 4;38(7):1335–1343. doi: 10.1007/s00259-011-1765-5

Fig. 2.

Fig. 2

In vivo investigation of 64Cu-DOTA-TRC105 in 4T1 tumour-bearing mice. a Serial coronal PET images of 4T1 tumour-bearing mice at 4, 24, and 48 h post-injection of 64Cu-DOTA-TRC105, TRC105 before 64Cu-DOTA-TRC105 (i.e. blocking), and 64Cu-DOTA-cetuximab. Tumors are indicated by arrowheads. b Representative PET/CT images of 64Cu-DOTA-TRC105 in 4T1 tumour-bearing mice at 24 h post-injection. c Time-activity curves of the tumour, liver, blood, and muscle upon intravenous injection of 64Cu-DOTA-TRC105 into 4T1 tumour-bearing mice (n = 3). d Comparison of 4T1 tumour uptake of 64Cu-DOTA-TRC105, 64Cu-DOTA-TRC105 with a blocking does of TRC105, and 64Cu-DOTA-cetuximab. *: P < 0.05 (n = 3).